Through this multi-year collaboration the partners are launching fifty leading Ashoka social entrepreneurs across the world, combining the creativity and knowledge of both partners to envision the future of the health arena, spotting and launching hundreds of promising young health change makers, giving 25 Boehringer Ingelheim executives 6-month opportunities to work in the organizations of top heath social entrepreneurs.

FORBES: Three Ways to Secure Your Social License to Operate in 2013

The split ends a decades-long partnership that appeared to unravel after Lilly signed a deal earlier this year with Boehringer Ingelheim to jointly develop and sell several diabetes compounds that are in mid- and late-stage development, including a Boehringer oral diabetes agent known as linagliptin.

FORBES: Lilly And Amylin End Their Bad Marriage

The main point of the article is to explain why FDA is not taking action against Spiriva (generic name: tiotropium), a treatment for chronic obstructive pulmonary disorder sold by Boehringer Ingelheim and Pfizer, despite a meta-analysis that raised concerns.

FORBES: FDA Asks For "Restraint" On Drug Safety Worries